The Bladder Cancer Advocacy Network (BCAN) has announced a Translational Clinical Trial Award (TCTA) for supporting patient-focused research to transform bladder cancer care. 

To aid bladder cancer patients and families, this award will offer a maximum of $3m grant over a period of 36 months. 

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It is intended to modify the standard of care in bladder cancer, reduce overtreatment and impact patient outcomes.

The BCAN grant will aid in enhancing outcomes for nearly 712,000 bladder cancer patients in the US.

BCAN board member Duncan Alexander is making generous funding for this award.

See Also:

Through the $3m grant, the network plans to increase the urgency in the bladder cancer research process and back projects with new approaches that are not likely to receive funding from industry or other sponsors. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This funding will support translational research and clinical trials and have a quick impact on bladder cancer therapies and medical care strategies, instead of backing basic research which offers general knowledge and understanding of an ailment.

Furthermore, this kind of award is meant to assist initiatives that are realistic and that have increased chances of meeting specified objectives. 

The network plans to announce the recipients of the grant in February next year.

BCAN CEO Andrea Maddox-Smith said: “This award will propel new thinking and approaches to how bladder cancer is diagnosed and treated. 

“Duncan’s abundant generosity aims to ease the burden of thousands of the more than 712,000 people impacted by bladder cancer in the US.”